IndustryCompany release

Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC

🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Mon 16 Nov 2026

The company's latest investor deck reports first dosing in the registrational study, a 43% confirmed response rate in earlier-line data, and an obesity candidate, CRB-913, with about $115M in cash.

Corbus Pharmaceuticals has updated its corporate presentation, with figures as of 30 September 2026, setting out progress across its oncology and obesity programmes. The lead oncology asset is sutantatug envedotin (SUTA-E), an antibody-drug conjugate directed at Nectin-4.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Corbus Pharmaceuticals Holdings, Inc. ↗

Article written by VigiEye from the official source (Corbus Pharmaceuticals Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →